• Reverse split ratio: 100:1, i.e. one hundred (100) old shares give one (1) new share
• Date on which the corporate action was made public: 30 April 2024
• Date of approval: 23 May 2024 (AGM)
• Last day including right: 29 May 2024 (trading inclusive right of reverse split)
• Ex-date: 30 May 2024 (trading exclusive right of reverse split)
• Record date: 31 May 2024
• New number of shares outstanding after reverse share split: 39,087,116

In connection with the reverse share split, the Company's shares will be transferred to a new ISIN.

• Issuer: BerGenBio ASA
• Previous ISIN: NO 001 0650013
• New ISIN: NO 001 3251173
• Date of ISIN change: 30 May 2024

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Continuing Obligations pursuant to Oslo Rule Book II.